Encompass Health Corporation (EHC) saw its stock price soar 5.22% on Friday in the pre-market trading session, outperforming the broader market. This surge can be attributed to positive analyst commentary following the company's recent quarterly earnings report.
Barclays raised its price target on EHC to $118 from $116 while maintaining an Overweight rating on the shares. The analysts cited the company's strong Q4 performance as the driving factor behind their increased price target.
Additionally, Truist Financial's David S. Macdonald reiterated a Buy rating on Encompass Health, expressing confidence in the company's growth prospects. Macdonald's report highlighted the company's solid financials and positive outlook.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.